Difference between revisions of "Classical Hodgkin lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "_99|" to "_999|") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 74: | Line 74: | ||
# '''EORTC 20884:''' Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; [[Study_Groups#EORTC|EORTC]] Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. [https://doi.org/10.1056/NEJMoa022628 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12802025/ PubMed] | # '''EORTC 20884:''' Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; [[Study_Groups#EORTC|EORTC]] Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. [https://doi.org/10.1056/NEJMoa022628 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12802025/ PubMed] | ||
# Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9. Epub 2004 Aug 17. [http://www.bloodjournal.org/content/104/12/3483.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15315964/ PubMed] | # Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9. Epub 2004 Aug 17. [http://www.bloodjournal.org/content/104/12/3483.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15315964/ PubMed] | ||
| − | # '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [https://doi.org/10.1200/jco.2010.33.9549 link to original article] [https://pubmed.ncbi.nlm.nih.gov/21990399/ PubMed] [https://clinicaltrials.gov/ | + | # '''GHSG HD12:''' Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. [https://doi.org/10.1200/jco.2010.33.9549 link to original article] [https://pubmed.ncbi.nlm.nih.gov/21990399/ PubMed] [https://clinicaltrials.gov/study/NCT00265031 Clinical Trial Registry] |
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://doi.org/10.1016/S2352-3026(18)30140-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290903/ PubMed] | ## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://doi.org/10.1016/S2352-3026(18)30140-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290903/ PubMed] | ||
<!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] --> | <!-- # '''Abstract:''' Radford, John, Barrington, Sally, Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter, Wimperis, Jennie, Coltart, Stewart, Culligan, Dominic, Lister, Andrew, Bessell, Eric, Kruger, Anton, Popova, Bilyana, Hancock, Barry, Hoskin, Peter, Illidge, Timothy, O'Doherty, Michael. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a 'Negative' PET Scan After 3 cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012 120: 547 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/547 link to original abstract] --> | ||
| − | # '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://doi.org/10.1056/NEJMoa1408648 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25901426/ PubMed] [https://clinicaltrials.gov/ | + | # '''UK NCRI RAPID:''' Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. [https://doi.org/10.1056/NEJMoa1408648 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25901426/ PubMed] [https://clinicaltrials.gov/study/NCT00943423 Clinical Trial Registry] |
| − | # '''EORTC-GELA H9-F:''' Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. Epub 2017 Oct 27. [https://doi.org/10.1016/j.ijrobp.2017.10.015 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29229324/ PubMed] [https://clinicaltrials.gov/ | + | # '''EORTC-GELA H9-F:''' Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. Epub 2017 Oct 27. [https://doi.org/10.1016/j.ijrobp.2017.10.015 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29229324/ PubMed] [https://clinicaltrials.gov/study/NCT00005584 Clinical Trial Registry] |
=Maintenance after upfront therapy= | =Maintenance after upfront therapy= | ||
| Line 135: | Line 135: | ||
===References=== | ===References=== | ||
| − | # '''AETHERA:''' Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. [https://doi.org/10.1016/S0140-6736(15)60165-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25796459/ PubMed] [https://clinicaltrials.gov/ | + | # '''AETHERA:''' Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. [https://doi.org/10.1016/S0140-6736(15)60165-9 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25796459/ PubMed] [https://clinicaltrials.gov/study/NCT01100502 Clinical Trial Registry] |
## '''HRQoL analysis:''' Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. Epub 2016 Sep 21. [https://doi.org/10.1111/bjh.14316 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27649689/ PubMed] | ## '''HRQoL analysis:''' Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. Epub 2016 Sep 21. [https://doi.org/10.1111/bjh.14316 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27649689/ PubMed] | ||
## '''Update:''' Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. Epub 2018 Sep 28. [http://www.bloodjournal.org/content/132/25/2639.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/30266774/ PubMed] | ## '''Update:''' Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. Epub 2018 Sep 28. [http://www.bloodjournal.org/content/132/25/2639.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/30266774/ PubMed] | ||
| − | # '''PATH:''' von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. [https://doi.org/10.1080/10428194.2016.1182164 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27184350/ PubMed] [https://clinicaltrials.gov/ | + | # '''PATH:''' von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. [https://doi.org/10.1080/10428194.2016.1182164 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27184350/ PubMed] [https://clinicaltrials.gov/study/NCT01034163 Clinical Trial Registry] |
[[Category:Classical Hodgkin lymphoma regimens]] | [[Category:Classical Hodgkin lymphoma regimens]] | ||
Revision as of 01:36, 25 June 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main Hodgkin lymphoma page for current regimens.
Consolidation after upfront therapy
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Young et al. 1973 | 1967-1972 | Phase 3 (C) | Intermittent BCNU | Did not meet efficacy endpoints |
| Intermittent MOPP | Did not meet efficacy endpoints | |||
| Aleman et al. 2003 (EORTC 20884) | 1989-2000 | Phase 3 (C) | IFRT | Did not meet primary endpoint of RFS36 |
| Straus et al. 2004 | 1990-2000 | Phase 3 (C) | EFRT | Might have inferior OS |
| Thomas et al. 2017 (EORTC-GELA H9-F) | 1998-2004 | Phase 3 (E-de-esc) | IFRT x 20 Gy | Not reported |
| IFRT x 36 Gy | Inferior RFS | |||
| Borchmann et al. 2011 (GHSG HD12) | 1999-2003 | Phase 3 (C) | See link | See link |
| Radford et al. 2015 (UK NCRI RAPID) | 2003-2010 | Phase 3 (C) | IFRT | Inconclusive whether non-inferior PFS36 |
No further treatment.
Preceding treatment
- Young et al. 1973: MOPP
- EORTC 20884: MOPP-ABV x 6 to 8
- Straus et al. 2004: ABVD x 6
- GHSG HD12: Escalated BEACOPP x 8 versus Escalated BEACOPP x 4, then BEACOPP x 4
- UK NCRI RAPID: ABVD x 3
- EORTC-GELA H9-F: EBVP x 6
References
- Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973 Jun 16;1(7816):1339-43. link to original article PubMed
- EORTC 20884: Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; EORTC Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406. link to original article PubMed
- Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9. Epub 2004 Aug 17. link to original article PubMed
- GHSG HD12: Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011 Nov 10;29(32):4234-42. Epub 2011 Oct 11. link to original article PubMed Clinical Trial Registry
- Update: von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. link to original article PubMed
- UK NCRI RAPID: Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607. link to original article contains dosing details in abstract PubMed Clinical Trial Registry
- EORTC-GELA H9-F: Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. Epub 2017 Oct 27. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
Maintenance after upfront therapy
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Sokal et al. 1974 | 1965-1967 | Randomized, <20 pts in this subgroup (C) | BCG | Inferior PFS |
Note: this study was open to patients with "malignant lymphoma" but the majority had Hodgkin disease.
References
- Sokal JE, Aungst CW, Snyderman M. Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med. 1974 Dec 5;291(23):1226-30. link to original article PubMed
Maintenance after salvage therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| von Treskckow et al. 2016 (PATH) | 2010-2011 | Phase 3 (C) | Panobinostat | Did not meet primary endpoint of DFS1 |
| Moskowitz et al. 2015 (AETHERA) | 2010-2012 | Phase 3 (C) | Brentuximab vedotin | Inferior PFS |
1PATH had a very low accrual and was not powered to investigate the original primary endpoint (DFS).
No further active antineoplastic treatment after transplant.
Preceding treatment
References
- AETHERA: Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. Epub 2015 Mar 18. Erratum in: Lancet. 2015 Aug 8;386(9993):532. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
- HRQoL analysis: Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. Epub 2016 Sep 21. link to original article link to PMC article PubMed
- Update: Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. Epub 2018 Sep 28. link to original article PubMed
- PATH: von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017 Jan;58(1):222-225. Epub 2016 May 17. link to original article PubMed Clinical Trial Registry